Drug in Trials Could Finally Treat Hepatitis E Virus

Scientists may have found the first effective treatment for a virus that infects millions and has eluded doctors for decades.

Hepatitis E affects people worldwide, leading to roughly 70,000 deaths each year. Despite its serious impact, there's currently no approved vaccine or specific medication to fight it.

Now researchers from Germany and China have discovered that bemnifosbuvir, a drug already in clinical trials for hepatitis C, effectively stops hepatitis E from spreading in the body. The team tested about 500 antiviral compounds using an engineered virus that glows when it replicates, making it easy to see which drugs worked.

Bemnifosbuvir stood out immediately. The drug mimics the building blocks of genetic material, essentially tricking the virus into using fake parts that prevent it from copying itself.

"With bemnifosbuvir we were able to see that the virus no longer replicated, while the treated cells remained healthy," said researcher Jungen Hu from Heidelberg University. Follow-up tests in animals confirmed the drug reduced both viral activity and liver inflammation.

The discovery matters most for people whose immune systems can't fight off the infection naturally. Organ transplant recipients, people living with HIV, and pregnant women face the highest risks from hepatitis E. For them, an infection that would clear up on its own in healthy people can become chronic and life threatening.

The Bright Side

Because bemnifosbuvir is already being tested in humans for hepatitis C, it could reach hepatitis E patients much faster than a completely new drug. The safety testing and manufacturing processes are already underway, potentially shaving years off the typical approval timeline.

If the ongoing hepatitis C trials prove successful, doctors could begin using the drug off label for hepatitis E patients who desperately need treatment options. That means people suffering from chronic infections might finally have hope within the next few years rather than waiting a decade or more for a brand new medication to go through the entire approval process.

The research team from Ruhr University Bochum, Heidelberg University Hospital, and Peking University published their findings in the journal Gut in March 2026. Their work received support from research programs in Germany and China focused on developing antiviral therapies.

For a disease that was first documented 70 years ago but still lacks basic treatment options, this breakthrough represents genuine progress toward saving thousands of lives each year.